Last reviewed · How we verify
Cannabinoids
At a glance
| Generic name | Cannabinoids |
|---|---|
| Sponsor | New York State Psychiatric Institute |
| Modality | Small molecule |
| Therapeutic area | Neuroscience |
| Phase | discontinued |
Approved indications
- Muscle Spasticity due to Multiple Sclerosis
Common side effects
Key clinical trials
- Interactions Between Cannabinoids and Cytochrome P450-Metabolized Drugs (Phase 1)
- Effects of Drugs on Stress Memories (EARLY/Phase 1)
- Use of a Product Containing the Cannabinoids CBD and THC as a Treatment Strategy for Alzheimer's Disease - Alzheimer's Disease and Cannabis Clinical Trial (DAZACANN) Open-Label Phase (Phase 1)
- Measuring Acute Drug Demand in Humans II (EARLY/Phase 1)
- The Pharmacokinetics and Pharmacodynamics of a Single Acute Dose of a Hemp-derived Oral Product With a 1:1 Ratio of CBD:CBD-A (Phase 1)
- A Monocentric, Controlled, Open Label, Phase I, First-in-human Trial to Investigate the Regional Distribution of [18F]RoSMA-18-d6 in the Brain and Spinal Cord to Assess Cannabinoid Type 2 Receptor (CB (Phase 1)
- A Double-blind, Randomized Placebo-controlled Trial to Evaluate Efficacy and Safety of Cannabidiol as an add-on Therapy for Treatment in Refractory Epileptic Crisis in Children and Adolescents (Phase 3)
- Correlation Between BDNF/CB1R Expression and Postoperative Pain and Recovery in Patients With Preoperative Sleep Disorders (N/A)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Cannabinoids CI brief — competitive landscape report
- Cannabinoids updates RSS · CI watch RSS
- New York State Psychiatric Institute portfolio CI